A team of scientists from Spain and the United Kingdom has identified a biomarker that predicts resistance to chemotherapy in certain cancer patients. The research, presented on June 23, 2025, aims to avoid ineffective treatments for patients with tumors such as those of the ovaries or prostate.
The study, published in Nature Genetics, highlights that the application of these biomarkers in clinical practice would reduce the side effects of chemotherapy and offer more effective treatments. The team developed a method to predict which patients will not respond to standard chemotherapy treatments.
The team has already tested its biomarkers with an emulated trial, using existing data from cancer patients who had already been treated with the chemotherapies analyzed in the study. The technology developed by the CNIO researchers must now be validated in a hospital setting, with plans for clinical trials in 2026.